A Single-Centre, Double-Blind, Double-Dummy, Randomised, Placebo-Controlled, Four-Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers

Trial Profile

A Single-Centre, Double-Blind, Double-Dummy, Randomised, Placebo-Controlled, Four-Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs AZD 5672 (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Actual end date (1 Jul 2009) added as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Additional lead trial centre (Quintiles Limited) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top